Form 4: Harvard Apparatus Regenerative Technology CEO Receives Stock
Insider Transaction (Form 4)
Junli He, CEO and a Director of Harvard Apparatus Regenerative Technology, Inc., reported multiple transactions in common stock on July 21, 2026.
Summary
- Grant/award: acquired 600,000 Nonqualified Stock Option (right to buy), time-based tranche on July 21, 2026; holds 600,000 after (Direct).
- Grant/award: acquired 600,000 Nonqualified Stock Option (right to buy), performance-based on July 21, 2026; holds 600,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Junli He — Director, Officer (CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-21 | Grant/award | Nonqualified Stock Option (right to buy), time-based tranche | 600,000 | — | — | 600,000 |
| 2026-07-21 | Grant/award | Nonqualified Stock Option (right to buy), performance-based | 600,000 | — | — | 600,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-21 | Grant/award (600,000 shares) |
| 2026-07-21 | Grant/award (600,000 shares) |
Keywords
insider transaction, Form 4, HRGN, Harvard Apparatus Regenerative Technology, Inc., neutral, Junli He
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.